Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Giardia intestinalis | Putative fructose-1,6-bisphosphate aldolase | Starlite/ChEMBL | No references |
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Candida albicans | fructose-bisphosphate aldolase | Putative fructose-1,6-bisphosphate aldolase | 323 aa | 358 aa | 22.6 % |
Candida albicans | fructose-bisphosphate aldolase | Putative fructose-1,6-bisphosphate aldolase | 323 aa | 358 aa | 22.6 % |
Mycobacterium leprae | Probable fructose bisphosphate aldolase Fba | Putative fructose-1,6-bisphosphate aldolase | 323 aa | 361 aa | 25.8 % |
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Mycobacterium tuberculosis | Probable fructose-bisphosphate aldolase Fba | Putative fructose-1,6-bisphosphate aldolase | 323 aa | 361 aa | 25.5 % |
Mycobacterium ulcerans | fructose-bisphosphate aldolase | Putative fructose-1,6-bisphosphate aldolase | 323 aa | 361 aa | 26.9 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | fructose-bisphosphate aldolase | 0.0172 | 0.3936 | 0.5 |
Echinococcus multilocularis | carboxylesterase 5A | 0.0284 | 0.7672 | 1 |
Echinococcus granulosus | carboxylesterase 5A | 0.0284 | 0.7672 | 1 |
Echinococcus granulosus | acetylcholinesterase | 0.0284 | 0.7672 | 1 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0284 | 0.7672 | 1 |
Echinococcus multilocularis | acetylcholinesterase | 0.0284 | 0.7672 | 1 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 1 | 0.5 |
Mycobacterium tuberculosis | Probable fructose-bisphosphate aldolase Fba | 0.0172 | 0.3936 | 0.5 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 1 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.0284 | 0.7672 | 1 |
Treponema pallidum | fructose-bisphosphate aldolase | 0.0353 | 1 | 0.5 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 1 | 0.5 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 1 | 0.5 |
Giardia lamblia | Fructose-bisphosphate aldolase | 0.0353 | 1 | 0.5 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 1 | 0.5 |
Entamoeba histolytica | fructose-1,6-bisphosphate aldolase, putative | 0.0353 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0284 | 0.7672 | 1 |
Brugia malayi | Carboxylesterase family protein | 0.0284 | 0.7672 | 1 |
Mycobacterium leprae | Probable fructose bisphosphate aldolase Fba | 0.0172 | 0.3936 | 0.5 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0284 | 0.7672 | 1 |
Loa Loa (eye worm) | carboxylesterase | 0.0284 | 0.7672 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0284 | 0.7672 | 1 |
Echinococcus multilocularis | acetylcholinesterase | 0.0284 | 0.7672 | 1 |
Brugia malayi | Carboxylesterase family protein | 0.0284 | 0.7672 | 1 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 1 | 0.5 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 1 | 0.5 |
Trichomonas vaginalis | fructose-bisphosphate aldolase, putative | 0.0353 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 1 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 3.5481 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia. (Class of assay: confirmatory) [Related pubchem assays: 2472, 2464 ] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.